BDX vs MDT
Becton Dickinson & Co. and Medtronic PLC, side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | BDX | MDT |
|---|---|---|
| Revenue | $21.8B | $36.4B |
| Net income | $1.7B | $4.8B |
| Gross margin | 45.4% | 65.0% |
| Net margin | 7.7% | 13.3% |
| Return on equity | 6.5% | 9.8% |
| Diluted EPS | $5.82 | $3.73 |
| Dividend / share | $4.16 | $2.84 |
| Payout ratio | 71.3% | 75.8% |
| Free cash flow | $2.7B | $5.4B |
| Equity | $25.4B | $49.5B |
| Net debt / equity | 0.73× | 0.53× |
| Current ratio | 1.11× | 2.13× |
| Revenue CAGR 5y | 6.3% | 3.8% |
| Profit CAGR 5y | 13.9% | 5.9% |
MDT bills 1.7× the revenue of BDX, and keeps more of each dollar of revenue as profit (13.3% against 7.7%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | BDX | MDT |
|---|---|---|
| FY2025 | $21.8B | $36.4B |
| FY2024 | $20.2B | $33.5B |
| FY2023 | $19.4B | $32.4B |
| FY2022 | $18.9B | $31.2B |
| FY2021 | $19.1B | $31.7B |
| FY2020 | $16.1B | $30.1B |
| FY2019 | $17.3B | $28.9B |
| FY2018 | $16.0B | $30.6B |
| FY2017 | $12.1B | $30.0B |
| FY2016 | $12.5B | $29.7B |
Bottom line
| Fiscal year | BDX | MDT |
|---|---|---|
| FY2025 | $1.7B | $4.8B |
| FY2024 | $1.7B | $4.7B |
| FY2023 | $1.5B | $3.7B |
| FY2022 | $1.8B | $3.8B |
| FY2021 | $2.1B | $5.0B |
| FY2020 | $874.0M | $3.6B |
| FY2019 | $1.2B | $4.8B |
| FY2018 | $311.0M | $4.6B |
| FY2017 | $1.1B | $3.1B |
| FY2016 | $976.0M | $4.0B |
14 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$14,524,000,000 | MDT |
| FY2024 | −$13,359,000,000 | MDT |
| FY2023 | −$12,992,000,000 | MDT |
| FY2022 | −$12,357,000,000 | MDT |
| FY2021 | −$12,555,000,000 | MDT |
| FY2020 | −$14,043,000,000 | MDT |
| FY2019 | −$11,623,000,000 | MDT |
| FY2018 | −$14,574,000,000 | MDT |
| FY2017 | −$17,860,000,000 | MDT |
| FY2016 | −$17,227,000,000 | MDT |
| FY2015 | −$18,551,000,000 | MDT |
| FY2014 | −$11,815,000,000 | MDT |
| FY2013 | −$8,951,000,000 | MDT |
| FY2012 | −$8,882,000,000 | MDT |
MDT has reported the higher revenue in every one of these 14 fiscal years. The gap has widened since the earliest year compared.
14 of 19 comparable fiscal years — a year missing data on either side is not counted.
14 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −5.6 pp | MDT |
| FY2024 | −5.5 pp | MDT |
| FY2023 | −3.8 pp | MDT |
| FY2022 | −2.7 pp | MDT |
| FY2021 | −5.0 pp | MDT |
| FY2020 | −6.6 pp | MDT |
| FY2019 | −9.5 pp | MDT |
| FY2018 | −13.3 pp | MDT |
| FY2017 | −1.2 pp | MDT |
| FY2016 | −5.7 pp | MDT |
| FY2015 | −5.5 pp | MDT |
| FY2014 | +0.8 pp | BDX |
| FY2013 | −2.0 pp | MDT |
| FY2012 | −5.7 pp | MDT |
The higher net margin has changed hands between BDX and MDT over this period.
14 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
BDX's net margin has been more volatile than MDT's over the 14 comparable fiscal years — 3.7 percentage points of standard deviation against 2.8.
14 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between BDX and MDT over these 14 fiscal years — BDX led in 1 and MDT in 13.
14 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
BDX's return on equity has been more volatile than MDT's over the 14 comparable fiscal years — 8.1 percentage points of standard deviation against 3.5.
14 of 18 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between BDX and MDT over these 14 fiscal years — BDX led in 7 and MDT in 7.
14 of 18 comparable fiscal years — a year missing data on either side is not counted.